Investors supporting Cyrano Therapeutics in revolutionizing the treatment of Smell Loss
Through investing in regenerative medicine with Cyrano Therapeutics, a pioneering clinical-stage company, you’re fueling efforts to revolutionize smell loss therapy. With a steadfast mission to restore the essential senses of smell and flavor, we are driven by groundbreaking research and advanced treatments aimed at bringing hope and healing to those suffering from anosmia. Our team of world-class researchers and clinicians leads the charge in this vital field, leveraging cutting-edge technology and compassionate care to develop therapies that make a real difference. Understanding the profound impact of smell loss on quality of life, Cyrano Therapeutics is dedicated to delivering innovative solutions that enhance patient outcomes and well-being. By investing in regenerative medicine through Cyrano Therapeutics, you are supporting a venture-backed leader poised to transform lives through science, pushing the boundaries of medical science and creating a brighter future for countless individuals.
Learn more about the investment firms behind Cyrano Therapeutics below:
Remiges Ventures
Based in Seattle and Tokyo, Remiges Ventures is a US-Japan cross-border venture capital firm focused on therapeutics. Remiges Ventures takes a lead position for the syndication of Series A or later-stage investment rounds globally and actively creates new companies based on innovative assets discovered at Japanese academic institutions. Remiges Ventures’ team is connected with serial entrepreneurs, KOLs in various therapeutic areas, key consultants, and major large pharmaceutical companies around the globe. The team actively participates in the value creation of its portfolio companies.
Lumira Ventures
Lumira executes a consistent, proven investment strategy as a lead investor and active partner with our portfolio companies. We focus on companies whose products offer transformative (not incremental) improvements to patient health outcomes and the promise of dramatic reductions in the cost of healthcare delivery. Our Canadian heritage helps us “skate to where the puck is going to be,” investing in the new science and clinical insights that we expect will be driving the next decade of patient care.
DeepWork Capital
DeepWork Capital invests in early-stage companies across the technology and life-science sectors, with a heavy geographic focus in the southeast region. Additionally, DeepWork serves as the Investment Manager for the State of Florida’s Venture Programs, collectively known as the Florida Opportunity Fund.
